Ke Lin

Dr. Ke Lin


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2024 in Heart Rhythm
Verified
Journal Article
Closed access
WRWeiqiang Ruan
Weiqiang Ruan
XZXiaoqin Zhou
Xiaoqin Zhou
JLJing Li
Jing Li
TWTing Wang
Ting Wang
HLHuizhen Liu
Huizhen Liu
KLKe Lin
Ke Lin

9 January 2025 in Global Heart
Verified
Journal Article
Open access
PDF file
XZXiaoqin Zhou
Xiaoqin Zhou
WRWeiqiang Ruan
Weiqiang Ruan
HJHui Jie
Hui Jie
HLHuizhen Liu
Huizhen Liu
TWTing Wang
Ting Wang
JLJing Lin
Jing Lin
Background: Ischemic heart disease (IHD) remains a significant global health challenge despite advancements in prevention and treatment. This study aims to comprehensively analyze global IHD mortality trends from 1990 to 2021 and projections for 2036, to support evidence-based decision-making for IHD prevention and management strategies across diverse contexts. Methods: Using data from the Global Burden of Disease Study 2021, we conducted multi-level analyses of IHD mortality trends: globally, across socio-demographic index (SDI) quintiles, 21 Global Burden of Disease (GBD) regions, and 204 countries. We performed age-period-cohort (APC), decomposition, risk factor, and frontier analysis. Bayesian APC modeling was used for projections to 2036. Results: The global age-standardized mortality rate (ASMR) for IHD decreased from 1990 to 2021 (EAPC: –1.301%, net drift: –1.1%) despite a 67.5% increase in total deaths. APC analysis revealed exponential growth in IHD mortality rates with age, with the inflection point at 62.5 years in low SDI regions and 77.5 years in high SDI regions. High SDI regions demonstrated significant period and cohort effects. Frontier analysis showed that Nauru and Ukraine were the countries with the highest effective differences. Decomposition analysis identified population growth and aging as primary factors increasing IHD mortality. High systolic blood pressure remained the leading global risk factor, with increasing contributions from high fasting plasma glucose and high body-mass index, especially in high SDI regions. Projections indicate continued global ASMR decrease by 2036, but with concerning increases in Eastern Europe and some African regions. Conclusions: This study reveals the complex global landscape of IHD, emphasizing that high SDI regions should focus on comprehensive care for older adults and managing metabolic risk factors such as diabetes and obesity, while low and middle SDI regions need to strengthen healthcare systems and implement early prevention strategies. Regions projecting mortality increases require urgent attention and interventions. HIGHLIGHTS What is new? Global IHD age-standardized mortality rates decreased from 1990 to 2021 (EAPC: –1.301%, net drift: –1.1%), despite a 67.5% increase in total deaths, reflecting advancements in care and ongoing challenges of population aging and growth. APC analysis showed exponential growth in IHD mortality rates with age across all SDI regions, with low SDI regions’ inflection point 15 years earlier than high SDI regions, suggesting prioritization of comprehensive care for the elderly in high SDI areas. Decomposition analysis showed South Asia and East Asia experienced the largest increases in IHD deaths, with epidemiological changes contributing to death increases rather than reductions, underscoring the need for effective policies to address population growth and aging in these rapidly developing regions. High systolic blood pressure remains the leading global risk factor for IHD, with increasing contributions from high fasting plasma glucose and high body-mass index, especially in high SDI regions. Projections indicate continued global ASMR decrease by 2036, but with concerning increases in Eastern Europe and some African regions, particularly Southern Sub-Saharan Africa, necessitating targeted interventions. What are the clinical implications? High SDI regions should focus on comprehensive care for the elderly and managing metabolic risks like hypertension, diabetes, and obesity. Low and middle SDI regions need to strengthen healthcare systems and implement early prevention to combat rising IHD mortality. Regions with projected increases, such as Eastern Europe and Southern Sub-Saharan Africa, require urgent policy interventions and resource allocation to address disparities and improve preventive care access.

12 June 2024 in ESC Heart Failure
Verified
Journal Article
Open access
WRWeiqiang Ruan
Weiqiang Ruan
XZXiaoqin Zhou
Xiaoqin Zhou
JLJing Li
Jing Li
HLHuizhen Liu
Huizhen Liu
TWTing Wang
Ting Wang
KLKe Lin
Ke Lin
Aims: Type 2 diabetes mellitus (T2DM) is associated with increased cardiovascular disease (CVD) risk, but whether T2DM directly causes adverse cardiac remodelling is uncertain. We performed a comprehensive Mendelian randomization (MR) analysis to investigate the causal relevance of T2DM to CVD outcomes and cardiac structure/function. Methods and results: Bidirectional two-sample MR was conducted using summary-level data from European-ancestry genome-wide association studies. The T2DM GWAS data included 80 154 cases and 853 816 controls from the DIAGRAM consortium. Outcomes included coronary artery disease (CAD), myocardial infarction (MI), stroke, heart failure, atrial fibrillation, and various quantitative cardiac imaging traits assessed by magnetic resonance imaging. MR analysis revealed causal associations between genetic predisposition to T2DM and increased risk of CAD (odds ratio [OR] 1.104, 95% confidence interval [CI] 1.078–1.130, P = 2.59e-16), MI (OR 1.129, 95% CI 1.094–1.166, P = 6.02e-14) and stroke (OR 1.086, 95% CI 1.064–1.109, P = 1.02e-14). These associations were validated in the FinnGen cohort (CAD: OR 1.117, 95% CI 1.075–1.158, P = 1.56e-9; MI: OR 1.132, 95% CI 1.083–1.184, P = 4.27e-8; stroke: OR 1.138, 95% CI 1.107–1.170, P = 3.52e-20). Multivariable MR show consistent findings (CAD: OR 1.063, 95% CI 1.031–1.097, P = 1.11e-4; MI: OR 1.088, 95% CI 1.042–1.135, P = 1.12e-4; stroke: OR 1.066, 95% CI 1.032–1.101, P = 1.18e-4) after adjusting for cardiometabolic traits. T2DM was causally associated with higher left ventricular mass index (β = 0.473, 95% CI 0.193 to 0.752, P = 0.001), lower indexed right atrial minimum (β = −0.048, 95% CI −0.073 to −0.022, P = 2.1e-5), and maximum (β = −0.042, 95% CI −0.065 to −0.019, P = 4.12e-5) areas. The effects on right atrial size remained significant after adjusting for risk factors (minimum area: β = −0.041, 95% CI −0.072 to −0.010, P = 0.009; maximum area: β = −0.039, 95% CI −0.069 to −0.008, P = 0.012). Both apolipoprotein A1 and SBP are important mediators in the causal relationship between T2DM and left ventricular mass index. No reverse causal associations were identified. Conclusions: Our MR study demonstrates that genetic liability to T2DM plays causal roles in CAD, MI, stroke, and cardiac structure changes including left ventricular hypertrophy and reduced right atrial dimensions. These findings provide genetic evidence supporting glycaemic control in T2DM to mitigate cardiovascular complications and adverse cardiac remodelling.

8 January 2024 in Global Heart
Verified
Journal Article
Open access
PDF file
XZXiaoqin Zhou
Xiaoqin Zhou
WRWeiqiang Ruan
Weiqiang Ruan
LZLijun Zhao
Lijun Zhao
KLKe Lin
Ke Lin
JLJing Li
Jing Li
GZGuiying Zhang
Guiying Zhang
Background: Chronic kidney disease (CKD) increases the risk of adverse cardiovascular outcomes. However, the causal relationships between renal function and cardiovascular diseases (CVD) remain incompletely understood. This study aimed to determine the causal relationships between genetic susceptibility to impaired renal function and the risk of CVD endpoints, as well as cardiac structure and function detectable by cardiac magnetic resonance imaging (CMR). Methods: Bidirectional Mendelian randomization (MR) analyses were conducted using summary-level data from genome-wide association studies. The exposures were blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio (UACR), and CKD. The outcomes included atrial fibrillation, coronary artery disease (CAD), myocardial infarction, heart failure, stroke, and various CMR parameters. Sensitivity analyses, multivariable MR adjusting for cardiometabolic traits, and replication in the FinnGen cohort were performed. Results: Elevated BUN levels (OR 1.505; 95% CI 1.077 to 2.103; P = 0.017) were causally associated with increased CAD risk, but this relationship was attenuated after adjusting for cardiometabolic traits. Increased UACR was causally linked to higher risks of CAD (OR 1.260; 95% CI 1.042 to 1.523; P = 0.017), myocardial infarction (OR 1.424; 95% CI 1.137 to 1.783; P = 0.002), and stroke (OR 1.182; 95% CI 1.012 to 1.379; P = 0.035), with the association for stroke remaining significant after multivariable adjustment. Reduced eGFR was causally related to decreases in ascending aorta diameter, proximal pulmonary artery diameter, right atrial size, left ventricular stroke volume, and right ventricular volumes, even after accounting for potential confounders. CKD was causally associated with a reduced pulmonary artery-to-aorta ratio and proximal pulmonary artery diameter. Conclusions: This comprehensive MR study establishes causal roles of genetic susceptibility to impaired renal function influencing cardiovascular outcomes and cardiac structure.

7 May 2024 in Heart & Lung
Verified
Journal Article
Closed access
WRWeiqiang Ruan
Weiqiang Ruan
XZXiaoqin Zhou
Xiaoqin Zhou
HLHuizhen Liu
Huizhen Liu
TWTing Wang
Ting Wang
GZGuiying Zhang
Guiying Zhang
KLKe Lin
Ke Lin

18 September 2020 in BMC Surgery
Verified
Journal Article
Open access
PDF file
LWLong Wang
Long Wang
LXLin Xie
Lin Xie
WRWeiqiang Ruan
Weiqiang Ruan
TLTao Li
Tao Li
CGChangping Gan
Changping Gan
KLKe Lin
Ke Lin
Background: This report presents updated data and mid-term follow-up information to a former study introducing the novel technique of percutaneous-perventricular device closure of doubly committed subarterial ventricular septal defect. Methods: Thirty-eight patients were added to the former series. There were 54 patients in total who had isolated doubly committed subarterial ventricular septal defects and underwent percutaneous-perventricular device closure. Closure outcomes and possible complications were measured in the hospital and during the 2.5-year follow-up. Results: Surgery was successful in 53 patients (98.1%). There was no death, residual shunt, new valve regurgitation or arrhythmia either perioperatively or during the entire follow-up period. Only one patient developed pericardial effusion and tamponade in the former series. The mean hospital stay was 3.2 ± 0.6 days (range, 3.0 to 6.0 days), and only one unsuccessful case needed blood transfusion (1.9%). Conclusions: The percutaneous-perventricular device closure of isolated doubly committed subarterial ventricular septal defects appeared to be safe. Close monitoring for bleeding is essential postoperatively, especially in younger patients. This technique is generally safe with acceptable mid-term follow-up.